Clinical Trial Update: Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

This ClinicalTrials.gov update reports on a Phase 3 diagnostic accuracy and safety study evaluating fluoroestradiol (FES) PET/CT for assessing estrogen receptor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fluoroestradiol (FES) (fluoroestradiol)

Snippet

Sponsor: Asan Medical Center | Conditions: Recurrent Breast Cancer, Stage IV Breast Cancer | Phase 3 | Status: COMPLETED